AVI Bio Pharma
From Wikipedia, the free encyclopedia
 |
This article or section is written like an advertisement. Please help rewrite this article from a neutral point of view per Wikipedia policy. Mark blatant advertising for speedy deletion with {{db-spam}}. (help, talk) |
AVI BioPharma Inc. is a medical research and drug development company with corporate offices in Portland, Oregon, United States, and laboratories in Corvallis, Oregon. It was incorporated in 1980. Its primary products in development are NeuGenes, drugs based on Morpholino oligos. AVI BioPharma Inc. is allied with the companies Exelixis Inc., DepoMed Inc., XTL Biopharmaceuticals Ltd., Abgenix Inc., and SuperGen, Inc.
NeuGene drugs are being tested for a wide range of applications including prevention of cardiac restenosis after angioplasty, treatment of coronary artery bypass grafts, treatment of polycystic kidney disease, and redirection of drug metabolism. NeuGene drugs have been used to inhibit replication of West Nile Virus, SARS, Hepatitis C, dengue fever, Ebola and Calicivirus, all of which are single stranded RNA viruses; clinical trials for West Nile Virus and Hepatitis C are ongoing. In addition to development of NeuGenes, AVI has conducted six human trials for colorectal and pancreatic cancers using their cancer vaccine AVICINE.
